Áttétes emlőrák: vizsgálatok itt: Belgium
34 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 2026. november 10.. Ask the study team whether a trial fits you.
- 1/2. fázisTaking peopleBeamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
- Where
- Brussels, Edegem, Leuven, Libramont-Chevigny, Liège, Namur
- Életkor
- 18 év and over
- People
- 910 worldwide
- Run by
- Boehringer Ingelheim
See details and how to joinNCT06324357 - 3. fázisTaking peoplePhase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
- Where
- Anderlecht, Edegem, Gent, Jette, Leuven, Libramont-Chevigny, Liège, Namur, Sint-Lambrechts-Woluwe, Sint-Niklaas, Verviers
- Életkor
- 18 év and over
- People
- 540 worldwide
- Run by
- Relay Therapeutics, Inc.
See details and how to joinNCT06982521 · EU 2025-523083-21-00 - 2/3. fázisTaking peopleRO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive
- Where
- Anderlecht, Brussels, Hasselt, Kortrijk, Leuven, Mechelen, Namur, Wilrijk
- Életkor
- 18 év and over
- People
- 650 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT07413939 · EU 2025-524498-17-00 - 3. fázisTaking peopleA Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
- Where
- Anderlecht, Hasselt, Kortrijk, Leuven, Namur, Ottignies, Sint-Niklaas
- Életkor
- 18 év and over
- People
- 800 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT07174336 · EU 2025-522791-92-00 - 2. fázisTaking peopleTo Study the Effect of Inavolisib in Combination With Fulvestrant in Participants With Breast Cancer
- Where
- Hasselt, Leuven, Namur, Sint-Lambrechts-Woluwe
- Életkor
- 18 év and over
- People
- 80 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT07368998 · EU 2025-522805-39-00 - 3. fázisTaking peopleA Phase 3, randomized, open-label, multicenter, controlled study to evaluate the efficacy and safety of zanidatamab in combination with physician’s choice chemotherapy compared to trastuzumab in combination with physician’s choice chemotherapy for the treatment (EmpowHER 303)
- Where
- Anderlecht, Charleroi, Edegem, Namur, Roeselare
- Életkor
- 18 év and over
- People
- 264 worldwide
- Run by
- Jazz Pharmaceuticals Ireland Limited
See details and how to joinNCT06435429 · EU 2023-508960-31-00 - 3. fázisTaking peopleEvaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
- Where
- Leuven, Namur, Sint-Lambrechts-Woluwe
- Életkor
- 18 év and over
- People
- 600 worldwide
- Run by
- LeonaBio
See details and how to joinNCT05696626 · EU 2023-503708-10-00 - 2. fázisTaking peopleHER2 Targeted Molecular Imaging in mBC and Other Metastatic Solid Carcinomas Using 68Ga-ABS011
- Where
- Aalst, Anderlecht, Brussels, Jette, Leuven, Sint-Lambrechts-Woluwe
- Életkor
- 18 év and over
- People
- 60 worldwide
- Run by
- Abscint NV/SA
See details and how to joinNCT06369831 · EU 2024-511419-22-00 - 3. fázisTaking peopleA Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy
- Where
- Charleroi, Edegem, Gent, Leuven, Namur, Sint-Lambrechts-Woluwe
- Életkor
- 18 év and over
- People
- 420 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT05646862 · EU 2022-502322-41-00 - 1/2. fázisTaking peopleA Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
- Where
- Charleroi, Gent, Leuven, Liège, Sint-Lambrechts-Woluwe
- Életkor
- 18 év and over
- People
- 680 worldwide
- Run by
- Daiichi Sankyo
See details and how to joinNCT06330064 · EU 2023-509632-26-00 - 1. fázisNot yet taking people in BelgiumA phase I study of [177Lu]Lu-DWJ155 and [68Ga]Ga-DWJ155 in patients with solid tumors
- Where
- Sint-Lambrechts-Woluwe
- Életkor
- 18 év and over
- People
- 64 worldwide
- Run by
- Novartis Pharma AG
See details and how to join2024-518348-19-00 · EU 2024-518348-19-00 - 3. fázisTaking peopleA Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
- Where
- Anderlecht, Brasschaat, Charleroi, Edegem, Hasselt, Leuven, Liège, Ottignies-Louvain-la-Neuve, Sint-Lambrechts-Woluwe, West-Vlaanderen
- Életkor
- 18 év and over
- People
- 400 worldwide
- Run by
- Pfizer
See details and how to joinNCT07062965 · EU 2025-520566-22-00 - 3. fázisTaking peopleA Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer
- Where
- Anderlecht, Brasschaat, Brussels, Charleroi, Gent, Hasselt, Jette, La Louvière, Liège, Mons, Namur, Sint-Lambrechts-Woluwe, Verviers
- Életkor
- 18 év and over
- People
- 230 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT05894239 · EU 2022-502046-28-00 - 3. fázisTaking peopleA Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
- Where
- Anderlecht, Brussels, Ghent, Hasselt, Namur
- Életkor
- 18 év and over
- People
- 1200 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06312176 · EU 2023-504918-29-00 - 3. fázisTaking peoplePhase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)
- Where
- Charleroi, Gent, Hasselt, Leuven, Sint-Lambrechts-Woluwe
- Életkor
- 18 év and over
- People
- 1180 worldwide
- Run by
- Celcuity Inc
See details and how to joinNCT06757634 · EU 2024-518933-28-01 - 1/2. fázisTaking peopleA Study of Patritumab Deruxtecan (HER3-DXd) in Combination With Trastuzumab Deruxtecan (T-DXd) in Participants With HR-Positive, HER2-Low or HER2-Ultralow Unresectable or Metastatic Breast Cancer
- Where
- Brussels, Leuven
- Életkor
- 18 év and over
- People
- 220 worldwide
- Run by
- Daiichi Sankyo
See details and how to joinNCT07701941 · EU 2024-517541-14-00 - 3. fázisTaking peoplePalazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
- Where
- Charleroi, Jette, Kortrijk, Liège, Sint-Lambrechts-Woluwe
- Életkor
- 18 év and over
- People
- 1000 worldwide
- Run by
- Olema Pharmaceuticals, Inc.
See details and how to joinNCT07085767 · EU 2025-522873-12-00 - No phaseTaking peopleEORTC Metastatic Breast Cancer Module Development
- Where
- Ghent
- Életkor
- 18 év and over
- People
- 568 worldwide
- Run by
- University of Leeds
See details and how to joinNCT07806266 - 1. fázisTaking peopleA First-in-Human phase 1, open-label, two-stage, randomized trial to assess the safety, tolerability, and biodistribution of [177Lu]Lu-ABY-271 in tumors and critical organs in subjects with HER2-positive metastatic breast cancer
- Where
- Anderlecht
- Életkor
- 18 év and over
- People
- 30 worldwide
- Run by
- Affibody AB
See details and how to join2024-518360-13-00 · EU 2024-518360-13-00 - 2. fázisTaking peopleLuMIERE: A Phase 1/2, Multicenter, Open label, Non randomized Study to Investigate Safety and Tolerability, Pharmacokinetics, Dosimetry, and Preliminary Activity of [177Lu]Lu-FAP-2286 in Participants with an Advanced Solid Tumor
- Where
- Anderlecht, Edegem, Leuven, Liège
- Életkor
- 18 év and over
- People
- 36 worldwide
- Run by
- Novartis Pharma AG
See details and how to joinNCT04939610 · EU 2023-508995-12-01 - 3. fázisTaking peopleA clinical study to evaluate the safety, efficacy, and impact on quality of life of capivasertib alongside routine endocrine treatment in patients with HR+/HER2- advanced breast cancer and disease progression despite prior hormone-based treatment (CAPIcorn)
- Where
- Anderlecht, Antwerp, Bruxelles-Capitale, Namur
- Életkor
- 18 év and over
- People
- 250 worldwide
- Run by
- WSG Women's Cancer Study Group GmbH
See details and how to join2024-511392-15-00 · EU 2024-511392-15-00 - No phaseTaking peopleDESTINY Breast Respond HER2-(Ultra)Low Europe
- Where
- Aalst, Auderghem, Bonheiden, Brasschaat, Bruges, Brussels, Haine-Saint-Paul, Hasselt, La Louvière, Liège, Namur, Ottignies, Sint-Niklaas, Verviers
- Életkor
- 18 év and over
- People
- 2295 worldwide
- Run by
- Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company
See details and how to joinNCT05945732 - 1/2. fázisTaking peopleA Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerability, and Efficacy of [177Lu]Lu-DPI-4452 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors
- Where
- Anderlecht, Leuven
- Életkor
- 18 év and over
- People
- 270 worldwide
- Run by
- Lumara Bio Oncologics GmbH
See details and how to joinNCT05706129 · EU 2023-504254-35-00 - No phaseTaking peopleAURORA: Aiming to Understand the Molecular Aberrations in Metastatic Breast Cancer.
- Where
- Brussels, Charleroi, Leuven, Liège, Namur
- Életkor
- 18 év and over
- People
- 1000 worldwide
- Run by
- Jules Bordet Institute
See details and how to joinNCT02102165 - 3. fázisTaking peoplePhase III Study to Evaluate the Safety, Efficacy, and Impact on Quality of Life of Capivasertib Alongside Standard-of-care Endocrine Treatment in Patients With HR+/HER2- Advanced Breast Cancer and Progression on Prior Endocrine-based Treatment
- Where
- Anderlecht
- Életkor
- 18 év and over
- People
- 250 worldwide
- Run by
- Women's Cancer Study Group GmbH
See details and how to joinNCT07281833